Cardinal Health, Inc. - CAH STOCK NEWS

The Court has authorized a Summary Notice regarding a proposed $124 million settlement of a stockholder derivative action against Cardinal Health. The settlement aims to resolve claims made in In re Cardinal Health, Inc. Derivative Litig. The Court will hold a Settlement Hearing on October 4, 2022, to evaluate the Settlement's fairness and reasonableness. Stockholders as of May 25, 2022, can object by September 13, 2022. Importantly, benefits from this Settlement will benefit the company, not individual stockholders directly.

Cardinal Health (NYSE: CAH) will announce its fourth-quarter and year-end financial results for fiscal year 2022 on August 11, before the market opens. A webcast discussing these results is set for 8:30 a.m. Eastern the same day. The financial results are anticipated to provide insights into the company's performance in various healthcare sectors, which include pharmaceuticals and medical products. For details, visit Cardinal Health's Investor Relations.

Cardinal Health has acquired the Bendcare group purchasing organization (CPO-GPO) and made a minority investment in its management services organization (MSO) to enhance its Cornerstone Rheumatology™ GPO. This strategic move allows Cardinal Health to provide innovative solutions and robust specialty drug access to over 1,300 rheumatology providers nationwide. Although financial terms remain undisclosed, the acquisition aims to improve technology solutions and distribution for specialty practices, reinforcing Cardinal Health's position in the healthcare market.

Cardinal Health (NYSE: CAH) launched an innovative Reserved Inventory Program aimed at improving inventory management for respiratory diagnostics in anticipation of the upcoming flu, strep, and RSV seasons. This program, tailored to individual labs and health systems, utilizes historical data to predict inventory needs, thereby alleviating supply challenges faced during previous respiratory seasons. Feedback from pilot participants indicates a significant reduction in inventory constraints and a high satisfaction rate. The program promises to deliver consistent supply and reduce delays in respiratory testing products.

Cardinal Health released new research indicating severe burnout among oncologists, with nearly 90% reporting emotional exhaustion. Over half of oncologists feel more stressed post-COVID-19, and 30% have considered early retirement due to stress. The study highlights barriers like prior authorizations affecting patient care, with 90% citing it as a significant hurdle. Cardinal Health has invested $2.6 million in mental health initiatives and aims to support oncologists in managing stress to mitigate the projected physician shortage by 2033.

Cardinal Health (NYSE: CAH) has announced a new distribution center in Grove City, Ohio, enhancing its at-Home Solutions business. This facility, measuring 208,144 square feet, is designed with advanced logistics technology, including robotic storage and the Kinaxis® RapidResponse® platform. It aims to support the growing demand for home healthcare, creating approximately 100 jobs by November 2022. This investment is part of a multi-year strategy to expand Cardinal Health's distribution network in Central Ohio, improving operational efficiencies and customer service.

Cardinal Health (NYSE: CAH) has announced a quarterly dividend of $0.4957 per share, approved by its Board of Directors. This dividend will be paid on July 15, 2022, to shareholders on record as of July 1, 2022. With a robust operational presence in over 30 countries and approximately 44,000 employees, Cardinal Health remains a crucial player in healthcare distribution and services. This dividend reflects the company's commitment to returning value to shareholders while maintaining a strong position in the healthcare sector.

Cardinal Health reported Q3 FY22 revenues of $44.8 billion, a 14% increase from last year. However, the company faced a GAAP operating loss of $97 million, mainly due to a $474 million non-cash goodwill impairment in the Medical segment. Non-GAAP operating earnings fell 21% to $545 million, while non-GAAP diluted EPS decreased 5% to $1.45. The company finalized an opioid settlement costing up to $6 billion over 18 years. FY22 guidance was adjusted, projecting non-GAAP EPS of $5.15 to $5.25 and Medical segment profit decline of 45-55%.

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Washington Attorney General, agreeing to pay up to $518 million. This payment resolves lawsuits filed by the state and its subdivisions, allowing for the dismissal of ongoing litigation. The settlement aligns with a previously announced agreement effective April 2, 2022, aimed at addressing a significant portion of opioid claims against the distributors. The companies dispute the allegations but see this as steps toward broader resolutions and relief for impacted communities.